In a setback to AbbVie (ABBV), a federal judge rebuked the drug maker for failing to cough up a ream of documents in a closely watched lawsuit that accuses the company of untoward behavior in creating a so-called patent thicket to protect its best-selling Humira medication.
At issue has been a simmering battle between AbbVie and Boehringer Ingelheim, which are locked in patent litigation, over access to internal AbbVie documents that discuss its strategy for bolstering Humira sales and fending off competition from lower-cost biosimilar alternatives.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
